{"id":399169,"date":"2020-12-14T10:16:48","date_gmt":"2020-12-14T15:16:48","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=399169"},"modified":"2020-12-14T10:16:48","modified_gmt":"2020-12-14T15:16:48","slug":"immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\/","title":{"rendered":"Immunovia publishes link to Webinar No. 3 on IMMray\u2122 PanCan-d: Verification Study and Clinical Use"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n LUND, Sweden<\/span>, Dec. 14, 2020<\/span> \/PRNewswire\/ —\u00a0Immunovia\u00a0AB (publ) (“Immunovia”) today published the link to the company’s third webinar in a series on IMMray\u2122 PanCan-d, Immunovia’s test for early detection of pancreatic cancer. The webinar will cover the IMMray\u2122 PanCan-d verification study results and its clinical use, including feedback from experts in pancreatic cancer and pancreatic diseases.<\/p>\n

\n Event Details:<\/b>\n <\/p>\n

\n Webinar No. 3 in Immunovia’s IMMray\u2122 PanCan-d Webinar Series: Verification Study and Clinical Use<\/b>\n <\/p>\n

\n Date and Time: December 17, 2020<\/span> at 15:00 CET<\/span><\/b>\n <\/p>\n

\n Moderator for the webinar: CEO Patrik Dahlen<\/span><\/b>\n <\/p>\n

\n Presenters:\u00a0<\/b>
\n Thomas King<\/span>, MD, PhD; Linda Mellby<\/span>, PhD, VP R&D; and Laura Chirica<\/span>, CCO, PhD, Immunovia
\u00a0
The Immunovia team will host a live Q&A session immediately following the webinar. <\/p>\n

\n Link to live stream: <\/b>
\n https:\/\/financialhearings.com\/event\/13559<\/a>\n <\/p>\n

Following the webinar, a recording will be available on\u00a0Immunovia’s website<\/a>: www.immunovia.com<\/a>.<\/p>\n

\n For more information, please contact:<\/b>\n <\/p>\n

\n Patrik Dahlen<\/span>, CEO Immunovia
Email: patrik.dahlen@immunovia.com<\/a>
Tel: +46 73 376 76 64<\/p>\n

\n About Immunovia<\/b>\n <\/p>\n

Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on\u00a0Immunovia’s proprietary test platform called IMMray\u2122.\u00a0Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature”.<\/p>\n

The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund<\/span> University and CREATE Health Cancer Center, Sweden<\/span>.<\/p>\n

The first product, IMMray\u2122 PanCan-d, is undergoing clinical evaluation in some of the\u00a0world’s largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1<\/a>\u00a0and is currently in the final validation phase. The company aims for a sales start at the end of Q1 2021 with subsequent commercial testing in Q2.<\/p>\n

When validated, IMMray\u2122 PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome.<\/p>\n

Immunovia Dx Laboratories located in Marlborough, Massachusetts<\/span>, USA and Lund, Sweden<\/span> will provide laboratory testing services in two accredited reference laboratories.<\/p>\n

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com<\/a>.<\/p>\n

This information was brought to you by Cision http:\/\/news.cision.com<\/a><\/p>\n

\n https:\/\/news.cision.com\/immunovia-ab\/r\/immunovia-publishes-link-to-webinar-no–3-on-immray–pancan-d–verification-study-and-clinical-use,c3254542<\/a>\n <\/p>\n

The following files are available for download:<\/p>\n

\n\n\n
\n

\n
\n https:\/\/mb.cision.com\/Main\/13121\/3254542\/1348295.pdf<\/a>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n Press release (PDF)<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

\n \"Cision\" View original content:http:\/\/www.prnewswire.com\/news-releases\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use-301192166.html<\/a><\/p>\n

SOURCE Immunovia AB<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire LUND, Sweden, Dec. 14, 2020 \/PRNewswire\/ —\u00a0Immunovia\u00a0AB (publ) (“Immunovia”) today published the link to the company’s third webinar in a series on IMMray\u2122 PanCan-d, Immunovia’s test for early detection of pancreatic cancer. The webinar will cover the IMMray\u2122 PanCan-d verification study results and its clinical use, including feedback from experts in pancreatic cancer and pancreatic diseases. Event Details: Webinar No. 3 in Immunovia’s IMMray\u2122 PanCan-d Webinar Series: Verification Study and Clinical Use Date and Time: December 17, 2020 at 15:00 CET Moderator for the webinar: CEO Patrik Dahlen Presenters:\u00a0 Thomas King, MD, PhD; Linda Mellby, PhD, VP R&D; and Laura Chirica, CCO, PhD, Immunovia\u00a0The Immunovia team will host a live Q&A session immediately following the webinar. Link to … <\/p>\n

Continue reading “Immunovia publishes link to Webinar No. 3 on IMMray\u2122 PanCan-d: Verification Study and Clinical Use”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-399169","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nImmunovia publishes link to Webinar No. 3 on IMMray\u2122 PanCan-d: Verification Study and Clinical Use - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunovia publishes link to Webinar No. 3 on IMMray\u2122 PanCan-d: Verification Study and Clinical Use - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire LUND, Sweden, Dec. 14, 2020 \/PRNewswire\/ —\u00a0Immunovia\u00a0AB (publ) (“Immunovia”) today published the link to the company’s third webinar in a series on IMMray\u2122 PanCan-d, Immunovia’s test for early detection of pancreatic cancer. The webinar will cover the IMMray\u2122 PanCan-d verification study results and its clinical use, including feedback from experts in pancreatic cancer and pancreatic diseases. Event Details: Webinar No. 3 in Immunovia’s IMMray\u2122 PanCan-d Webinar Series: Verification Study and Clinical Use Date and Time: December 17, 2020 at 15:00 CET Moderator for the webinar: CEO Patrik Dahlen Presenters:\u00a0 Thomas King, MD, PhD; Linda Mellby, PhD, VP R&D; and Laura Chirica, CCO, PhD, Immunovia\u00a0The Immunovia team will host a live Q&A session immediately following the webinar. Link to … Continue reading "Immunovia publishes link to Webinar No. 3 on IMMray\u2122 PanCan-d: Verification Study and Clinical Use"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-14T15:16:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO23004&sd=2020-12-14\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immunovia publishes link to Webinar No. 3 on IMMray\u2122 PanCan-d: Verification Study and Clinical Use\",\"datePublished\":\"2020-12-14T15:16:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\\\/\"},\"wordCount\":428,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO23004&sd=2020-12-14\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\\\/\",\"name\":\"Immunovia publishes link to Webinar No. 3 on IMMray\u2122 PanCan-d: Verification Study and Clinical Use - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO23004&sd=2020-12-14\",\"datePublished\":\"2020-12-14T15:16:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO23004&sd=2020-12-14\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO23004&sd=2020-12-14\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immunovia publishes link to Webinar No. 3 on IMMray\u2122 PanCan-d: Verification Study and Clinical Use\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immunovia publishes link to Webinar No. 3 on IMMray\u2122 PanCan-d: Verification Study and Clinical Use - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\/","og_locale":"en_US","og_type":"article","og_title":"Immunovia publishes link to Webinar No. 3 on IMMray\u2122 PanCan-d: Verification Study and Clinical Use - Market Newsdesk","og_description":"PR Newswire LUND, Sweden, Dec. 14, 2020 \/PRNewswire\/ —\u00a0Immunovia\u00a0AB (publ) (“Immunovia”) today published the link to the company’s third webinar in a series on IMMray\u2122 PanCan-d, Immunovia’s test for early detection of pancreatic cancer. The webinar will cover the IMMray\u2122 PanCan-d verification study results and its clinical use, including feedback from experts in pancreatic cancer and pancreatic diseases. Event Details: Webinar No. 3 in Immunovia’s IMMray\u2122 PanCan-d Webinar Series: Verification Study and Clinical Use Date and Time: December 17, 2020 at 15:00 CET Moderator for the webinar: CEO Patrik Dahlen Presenters:\u00a0 Thomas King, MD, PhD; Linda Mellby, PhD, VP R&D; and Laura Chirica, CCO, PhD, Immunovia\u00a0The Immunovia team will host a live Q&A session immediately following the webinar. Link to … Continue reading \"Immunovia publishes link to Webinar No. 3 on IMMray\u2122 PanCan-d: Verification Study and Clinical Use\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-14T15:16:48+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO23004&sd=2020-12-14","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immunovia publishes link to Webinar No. 3 on IMMray\u2122 PanCan-d: Verification Study and Clinical Use","datePublished":"2020-12-14T15:16:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\/"},"wordCount":428,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO23004&sd=2020-12-14","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\/","name":"Immunovia publishes link to Webinar No. 3 on IMMray\u2122 PanCan-d: Verification Study and Clinical Use - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO23004&sd=2020-12-14","datePublished":"2020-12-14T15:16:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO23004&sd=2020-12-14","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO23004&sd=2020-12-14"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovia-publishes-link-to-webinar-no-3-on-immray-pancan-d-verification-study-and-clinical-use\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immunovia publishes link to Webinar No. 3 on IMMray\u2122 PanCan-d: Verification Study and Clinical Use"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/399169","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=399169"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/399169\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=399169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=399169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=399169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}